CARsgen Therapeutics (2171.HK)

Executive Summary

CARsgen Therapeutics is a clinical-stage biopharmaceutical company pioneering CAR T-cell therapies for both solid tumors and hematologic malignancies. The company's pipeline includes autologous and allogeneic candidates targeting BCMA (CT053) for multiple myeloma, Claudin18.2 (CT041) for gastric and pancreatic cancers, and other novel targets. CT053 has demonstrated promising efficacy and safety in relapsed/refractory multiple myeloma, with a pivotal trial in China nearing completion, while CT041 continues to show durable responses in Claudin18.2-positive solid tumors. CARsgen is advancing its proprietary allogeneic platform to reduce manufacturing costs and expand patient access. Despite challenges in the competitive CAR T landscape, the company's focus on next-generation targets and global expansion positions it as a key player in cell therapy. Recent regulatory setbacks in the US have been mitigated by progress in China, where potential approvals could unlock significant value.

Upcoming Catalysts (preview)

• Q3 2026CT053 NDA submission in China for multiple myeloma80% success
• Q4 2026Interim Phase 2 data for CT041 in gastric cancer60% success
• Q1 2027Allogeneic CAR T IND filing or initial clinical data50% success